Logo image of ACIU

AC IMMUNE SA (ACIU) Stock Fundamental Analysis

NASDAQ:ACIU - Nasdaq - CH0329023102 - Common Stock - Currency: USD

1.64  -0.02 (-1.2%)

After market: 1.64 0 (0%)

Fundamental Rating

3

Taking everything into account, ACIU scores 3 out of 10 in our fundamental rating. ACIU was compared to 568 industry peers in the Biotechnology industry. The financial health of ACIU is average, but there are quite some concerns on its profitability. ACIU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACIU had negative earnings in the past year.
ACIU had a positive operating cash flow in the past year.
In the past 5 years ACIU always reported negative net income.
ACIU had negative operating cash flow in 4 of the past 5 years.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

The Return On Assets of ACIU (-22.05%) is better than 77.29% of its industry peers.
The Return On Equity of ACIU (-45.35%) is better than 67.78% of its industry peers.
Industry RankSector Rank
ROA -22.05%
ROE -45.35%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

ACIU does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACIU has been increased compared to 1 year ago.
ACIU has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ACIU is higher compared to a year ago.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

ACIU has an Altman-Z score of -1.80. This is a bad value and indicates that ACIU is not financially healthy and even has some risk of bankruptcy.
ACIU has a Altman-Z score (-1.80) which is in line with its industry peers.
ACIU has a debt to FCF ratio of 0.08. This is a very positive value and a sign of high solvency as it would only need 0.08 years to pay back of all of its debts.
ACIU has a better Debt to FCF ratio (0.08) than 97.18% of its industry peers.
ACIU has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
ACIU has a Debt to Equity ratio of 0.04. This is in the lower half of the industry: ACIU underperforms 61.44% of its industry peers.
Although ACIU does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.08
Altman-Z -1.8
ROIC/WACCN/A
WACC5.06%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.71 indicates that ACIU should not have too much problems paying its short term obligations.
ACIU has a Current ratio of 1.71. This is in the lower half of the industry: ACIU underperforms 79.40% of its industry peers.
ACIU has a Quick Ratio of 1.71. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ACIU (1.71) is worse than 78.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

ACIU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.75%, which is quite good.
Looking at the last year, ACIU shows a very strong growth in Revenue. The Revenue has grown by 84.51%.
The Revenue for ACIU have been decreasing by -24.39% on average. This is quite bad
EPS 1Y (TTM)18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
Revenue 1Y (TTM)84.51%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%-92.32%

3.2 Future

ACIU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.45% yearly.
The Revenue is expected to grow by 57.79% on average over the next years. This is a very strong growth
EPS Next Y-57.47%
EPS Next 2Y-12.77%
EPS Next 3Y30.77%
EPS Next 5Y39.45%
Revenue Next Year-88.86%
Revenue Next 2Y-6.98%
Revenue Next 3Y58.63%
Revenue Next 5Y57.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ACIU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACIU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

99.82% of the companies in the same industry are more expensive than ACIU, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.08
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ACIU's earnings are expected to grow with 30.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.77%
EPS Next 3Y30.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACIU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AC IMMUNE SA

NASDAQ:ACIU (4/25/2025, 8:00:00 PM)

After market: 1.64 0 (0%)

1.64

-0.02 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-24 2025-04-24
Earnings (Next)08-04 2025-08-04
Inst Owners28.02%
Inst Owner Change-0.11%
Ins Owners3.06%
Ins Owner ChangeN/A
Market Cap164.67M
Analysts88
Price Target10.2 (521.95%)
Short Float %2.31%
Short Ratio7.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.66%
Min EPS beat(2)16.28%
Max EPS beat(2)125.04%
EPS beat(4)2
Avg EPS beat(4)-18.26%
Min EPS beat(4)-183.77%
Max EPS beat(4)125.04%
EPS beat(8)5
Avg EPS beat(8)-99.11%
EPS beat(12)8
Avg EPS beat(12)-62.17%
EPS beat(16)10
Avg EPS beat(16)-68.56%
Revenue beat(2)2
Avg Revenue beat(2)816.75%
Min Revenue beat(2)50.21%
Max Revenue beat(2)1583.29%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.44%
EPS NQ rev (1m)7.24%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-219.14%
EPS NY rev (3m)-106.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-94.9%
Revenue NY rev (3m)-93.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.98
P/FCF 2.08
P/OCF 2.06
P/B 1.21
P/tB 2.2
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)0.79
FCFY48.01%
OCF(TTM)0.79
OCFY48.43%
SpS0.33
BVpS1.35
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.05%
ROE -45.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 238.99%
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.08
Debt/EBITDA N/A
Cap/Depr 26.64%
Cap/Sales 2.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z -1.8
F-Score5
WACC5.06%
ROIC/WACCN/A
Cap/Depr(3y)38.45%
Cap/Depr(5y)62.34%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
EPS Next Y-57.47%
EPS Next 2Y-12.77%
EPS Next 3Y30.77%
EPS Next 5Y39.45%
Revenue 1Y (TTM)84.51%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%-92.32%
Revenue Next Year-88.86%
Revenue Next 2Y-6.98%
Revenue Next 3Y58.63%
Revenue Next 5Y57.79%
EBIT growth 1Y2.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.67%
EBIT Next 3Y-16.92%
EBIT Next 5Y-11.51%
FCF growth 1Y206.63%
FCF growth 3YN/A
FCF growth 5Y4.12%
OCF growth 1Y209%
OCF growth 3YN/A
OCF growth 5Y3.58%